Organization: Inimex Pharmaceuticals Inc

Inimex receives US$4.5 million in venture financing

Vancouver-based Inimex Pharmaceuticals Inc has received US$4.5 million in syndicated financing for the lead optimization and pre-clinical development of the first drug based on its innate immunity technology platform. The investment was made by a financing syndicate led by BDC Venture Capital and including the Canadian Medical Discoveries Fund and Working Opportunity Fund. Inimex’s platform…

Genome research project secures corporate backing

The largest project ever funded by Genome Canada — Functional Patho-genomics of Mucosal Immunity — has netted two corporate sponsors. Inimex Pharmaceuticals Inc of Vancouver and the newly created Pyxis Genomics Canada Inc (a subsidiary of Chicago-based Pyxis Genomics Inc) are contributing a total of $10.5 million for exclusive rights to commercialize discoveries arising from…